Compass Pathways Plc (CMPS) Stock Price & Analysis
Compass Pathways Plc (CMPS) fell 3.84% to USD 11.26 as of July 25, 2026 at 15:04 UTC, according to Nexqual real-time market data.
CMPS last closed at USD 11.71; the session ranged USD 11.01–11.89 on volume of 3,624,850 shares. Market capitalization is $1.52B, with a 52-week range of USD 3.92–15.4 (NMS). Source: Nexqual, July 25, 2026 at 15:04 UTC.
Key Statistics (as of July 25, 2026 at 15:04 UTC)
| Price | USD 11.26 |
|---|---|
| Change | ▼ 3.84% (down) |
| Previous Close | USD 11.71 |
| Open | USD 11.82 |
| Day Range | USD 11.01 – 11.89 |
| 52-Week Range | USD 3.92 – 15.4 |
| Volume | 3,624,850 shares |
| Market Cap | $1.52B |
| Exchange | NMS |
Technical Analysis (CMPS)
Nexqual's technical model rates CMPS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.17 (neutral) |
| vs SMA50 | Below (USD 12.39) |
| MACD | -0.19 (negative) |
Analyst Ratings (CMPS)
Wall Street analysts rate CMPS "Strong Buy" based on 15 analysts, with a mean price target of USD 24.47 (range USD 17–70), per Nexqual as of July 25, 2026 at 15:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 24.47 |
| High Target | USD 70 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (CMPS)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.31 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.32 ▲ beat |
| 2025-12-31 | USD -0.61 vs est -0.39 ▼ miss |
| 2025-09-30 | USD -0.38 vs est -0.41 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.37 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:04 UTC.
Financials & Fundamentals (CMPS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -68.48% |
| Debt / Equity | 16.32 |
| Current Ratio | 3.32 |
| Total Cash | $466.01M |
| Total Debt | $53.31M |
| Free Cash Flow | $33.07M |
Source: Nexqual, July 25, 2026 at 15:04 UTC.
Financial Health Score (CMPS)
Nexqual rates Compass Pathways Plc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $466M cash vs $53M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$160M |
| Efficiency | Critical — ROE -68%, ROA -25.6% |
Ownership (CMPS)
| Insider Ownership | +7.83% |
|---|---|
| Institutional Ownership | +72.77% |
| Shares Outstanding | 134.95M |
| Float | 101.49M |
| Short % of Float | +9.64% |
Source: Nexqual, July 25, 2026 at 15:04 UTC.
Leadership (CMPS)
Compass Pathways Plc is led by Kabir Kumar Nath M.A. (age 61), CEO & Executive Director, per Nexqual as of July 25, 2026 at 15:04 UTC.
| CEO & Executive Director | Kabir Kumar Nath M.A. (age 61) |
|---|---|
| Chief Financial Officer | Teri Loxam (age 52) |
| Senior Vice President of Investor Relations | Stephen D. Schultz |
Major Backers & Investors (CMPS)
Notable institutional backers of Compass Pathways Plc include Deep Track Capital, Lp, RTW Investments LP, ARK Invest, according to Nexqual as of July 25, 2026 at 15:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 9.01% |
| RTW Investments LP | 7.88% |
| ARK Invest | 4.86% |
| Marshall Wace LLP | 2.99% |
| Tang Capital Management, LLC | 2.97% |
| BIT Capital GmbH | 2.59% |
| Millennium Management | 2.33% |
| GMT Capital Corp | 2.28% |
Source: Nexqual, July 25, 2026 at 15:04 UTC.
From Compass Pathways Plc's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
- Investigational COMP360 Psilocybin Clinical Development Programs COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | USD 43.17 | ▼ 1.14% |
| HELP | Cybin Inc. | USD 7.62 | ▼ 2.56% |
| AACG | ATA Creativity Global | USD 0.89 | ▼ 2.52% |
| ATAI | AtaiBeckley Inc. | USD 7.18 | ▲ 0% |
| GHRS | GH Research PLC | USD 27.28 | ▼ 4.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:04 UTC. This page is informational and not investment advice.